Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
645.00    7.00 (1.10%)
Bid:
647.00
Ask:
648.00
Spread: 1.00 (0.155%)
Market Cap: £525.00m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Trading Update

5 Mar 2026 07:00

RNS Number : 4763V
Bloomsbury Publishing PLC
05 March 2026
 

BLOOMSBURY PUBLISHING PLC 

("Bloomsbury" or "the Company")

 

Sarah J. Maas announces the publication dates of her next two novels will be within the next year

Trading Update: FY 2025/26 in line, FY 2026/27 expected to be materially ahead of expectations

 

Bestselling author Sarah J. Maas has announced the publication dates of the next two novels in her A Court of Thorns and Roses ('ACOTAR') series which will be published on 27 October 2026 and 12 January 2027.

Nigel Newton, Chief Executive of Bloomsbury, commented, "Fans all over the world are eagerly anticipating reading the next books in the ACOTAR series and we are very excited about this news. Publishing two novels within 11 weeks of each other from a bestselling author is almost unprecedented in publishing history."

Sarah J. Maas was the highest selling author in the United States in 2024 according to Circana sales data and the No.1 bestselling Fantasy author in the UK in 2025. All 16 of Sarah J. Maas' previous novels are published by Bloomsbury.

Bloomsbury expects group profit for the year ended 28 February 2026 to be in-line with market consensus expectations.* This reflects the benefits of Bloomsbury's portfolio of portfolios strategy and includes a strong performance from the Academic division. Looking ahead, group profit for the year ending 28 February 2027 is now expected to be materially ahead of market consensus expectations.*

Further details on trading and outlook will be provided with the Company's Preliminary Results announcement scheduled for 20 May 2026.

Note

* The Board considers market consensus expectation (before this publication) for profit before taxation and highlighted items for the year ending 28 February 2026 to have been £44.3m and the year ending 28 February 2027 to have been £44.5m.

For further information, please contact:

Bloomsbury Publishing Plc

 

Tamsin Garrity, Group Investor Relations Director

tamsin.garrity@bloomsbury.com

Hudson Sandler

Dan de Belder / Hattie Dreyfus / Emily Brooker

bloomsbury@hudsonsandler.com

Disclaimer

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

The information in this announcement has not been audited or otherwise independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this announcement, or its contents, or otherwise arising in connection with this announcement.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company.

Certain statements, statistics and projections in this announcement are or may be forward looking. By their nature, forward?looking statements involve a number of risks, uncertainties or assumptions that may or may not occur and actual results or events may differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance should not be placed on any forward-looking statement. Accordingly, forward-looking statements contained in this announcement regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which are based on the knowledge and information available only at the date of this announcement's preparation.

The Company does not undertake any obligation to update or keep current the information contained in this announcement, including any forward?looking statements, or to correct any inaccuracies which may become apparent and any opinions expressed in it are subject to change without notice.

References in this announcement to other reports or materials, such as a website address, have been provided to direct the reader to other sources of information on Bloomsbury Publishing Plc which may be of interest. Neither the content of Bloomsbury's website nor any website accessible by hyperlinks from Bloomsbury's website nor any additional materials contained or accessible thereon, are incorporated in, or form part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFIFVEVTIEIIR
Date   Source Headline
20th Mar 20257:00 amRNSTrading Update and Board Appointment
3rd Mar 20257:00 amRNSNotice of Trading Update
24th Feb 20254:27 pmRNSHolding(s) in Company
14th Feb 202510:05 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jan 20257:00 amRNSBloomsbury reaches new agreement with Amazon
16th Dec 202410:05 amRNSHolding(s) in Company
16th Dec 20249:55 amRNSHolding(s) in Company - Replacement
11th Dec 202410:24 amRNSDirector/PDMR Shareholding
9th Dec 20249:18 amRNSDirector/PDMR Shareholding
26th Nov 202411:44 amRNSHolding(s) in Company
26th Nov 202410:35 amRNSDirector/PDMR Shareholding
24th Oct 20247:00 amRNSUnaudited Interim Results
30th Sep 20247:00 amRNSNotice of Interim Results
2nd Sep 202411:31 amRNSDirector/PDMR Shareholding
29th Aug 20247:00 amRNSDirector/PDMR Shareholding
28th Aug 202410:57 amRNSDirector/PDMR Shareholding
16th Aug 20244:18 pmRNSAMENDMENT: BLOCK LISTING SIX MONTHLY RETURN
16th Aug 20249:42 amRNSBLOCK LISTING SIX MONTHLY RETURN
7th Aug 20245:36 pmRNSAwards under the 2023 Executive Share Plan
16th Jul 20243:41 pmRNSResults of the 2024 Annual General Meeting
16th Jul 20247:00 amRNSAGM Trading Update
14th Jun 20245:01 pmRNSAnnual Financial Report
14th Jun 20241:48 pmRNSBoard Appointment
29th May 20247:00 amRNSAcquisition
23rd May 20247:00 amRNSChairman Succession Announcement
23rd May 20247:00 amRNSAudited Preliminary Results
20th May 20247:00 amRNSInvestor Presentation
16th Feb 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Feb 20247:00 amRNSTrading Update
1st Feb 20243:11 pmRNSBloomsbury launches latest Sarah J. Maas novel
15th Jan 20247:00 amRNSBloomsbury Appoints Head of Investor Relations
12th Jan 202411:45 amRNSHolding(s) in Company
9th Jan 20244:10 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
15th Nov 20237:00 amRNSBlocklisting Application
31st Oct 20237:00 amRNSInvestor Presentation
26th Oct 20237:00 amRNSUnaudited Interim Results
9th Oct 20231:00 pmRNSBloomsbury playwright Jon Fosse wins Nobel Prize
22nd Sep 20231:26 pmRNSDirector/PDMR Shareholdings - Correction
14th Sep 20237:00 amRNSBloomsbury launches new book by Katherine Rundell
5th Sep 20237:00 amRNSDirector/PDMR Shareholding
1st Sep 20232:05 pmRNSDirector/PDMR Shareholding
30th Aug 20231:56 pmRNSDirector/PDMR Shareholding
29th Aug 20232:11 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20238:00 amRNSBloomsbury enjoys bestseller success
17th Aug 20234:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
18th Jul 20235:13 pmRNSResults of the 2023 Annual General Meeting
18th Jul 20237:00 amRNSAGM Trading Update
23rd Jun 20232:29 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.